BMC Pharmacology and Toxicology is calling for submissions to our Collection on Radiopharmaceuticals in medicine.

Radiopharmaceuticals are a class of radioisotopes-containing medicinal formulations used for targeted diagnosis and therapy that conventional medicine can’t match. Their development is driven by advances in radiochemistry, molecular pharmacology, and nuclear medicine. By combining radioisotopes with vector molecules and imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), radiopharmaceuticals provide advanced diagnostic options in many diseases, including cancer and cardiovascular disorders. Beyond diagnosis, the same molecular targets can be exploited for therapy, giving rise to the concept of theranostics, where a single agent or closely related pair enables both precise imaging and targeted treatment. As a vital component of modern medical practice, radiopharmaceuticals facilitate rapid early detection of diseases, guide treatment decisions, and improve patient outcomes.

Continued exploration in this field may lead to groundbreaking advancements in propelling personalized medicine and establishing associated standards for disease detection and treatment. This includes the discovery of novel radionuclides, innovative drug delivery systems, and refined targeting strategies. These advancements together with improved imaging technology provide more possibilities in clinical practice. All of these explorations aim to improve the safety, the specificity, and the precision of therapeutics, consolidating their role in personalized medicine, and propelling precision medicine.

Researchers are invited to submit their work to this Collection, showcasing innovative research on radiopharmaceuticals, their applications in diagnostics and therapy, and the impact they have on advancing nuclear medicine.

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

BMC Pharmacology and Toxicology is calling for submissions to our Collection on Neonatal and pediatric drug development and safety.

The recent surge of attention to neonatal and pediatric medication is mainly due to the recognition of distinct pharmacokinetics and pharmacodynamics in infants and children compared to adults. These variations can have a substantial impact on the safety and efficacy of medications. Insufficient clinical trials and limited access to licensed drugs for infants and kids can lead to less-than-ideal therapeutic choices and raise the possibility of adverse drug reactions. Hence, it is crucial to conduct in-depth research specifically designed for these vulnerable populations. Through this Collection, we aim to gather studies that further our knowledge of medication development and safety in neonatal and pediatric healthcare while promoting better clinical outcomes.

Continued exploration in this area is essential as advancements in drug formulation, delivery systems, and regulatory frameworks gain prominence. Recent initiatives, such as the establishment of pediatric research networks and the implementation of incentives for drug development in children, have made strides in filling these gaps. However, there remains an urgent need for comprehensive studies that not only assess the safety and efficacy of drugs but also consider the long-term effects of treatment in pediatric populations. By fostering collaboration among researchers, clinicians, and regulatory bodies, we can further enhance drug development processes that prioritize the health and safety of our youngest patients.

We encourage articles on various aspects of basic research, clinical trials, and health care.

Potential topics include, but are not limited to:

Innovative drug delivery systems for neonates

Assessing adverse drug reactions in pediatric populations

Strategies for enhancing drug safety in neonatal healthcare

Regulatory frameworks for pediatric drug development

Drug development and evaluation by pharmacokinetics, pharmacodynamics, and Population pharmacokinetics

Health care challenges in low and middle-income countries

Early drug exposure and health care of neonates, children, and adolescents

This Collection supports and amplifies research related to SDG 3: Good Health & Well-Being.

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.